Cycle on Jul 21, 2026

I am going to check the active threads for this topic to see if there are any specific questions, watches, or priorities we need to address in this cycle.

I will perform a web search to see if there are any recent updates regarding Saol Therapeutics' NDA resubmission for SL1009 (dichloroacetate / DCA) or its PDUFA date.

I will fetch the PR Newswire article and BioCentury article on Saol's SL1009 resubmission to see if there is any mention of an FDA review timeline or if there have been other recent regulatory pivots or news. Let's first search for more details or fetch these.

I see that Saol resubmitted the NDA on July 7, 2026. The PR says: "The FDA will assign a new action (PDUFA) date upon acceptance of the file." Let's see if there are any other very recent news or updates on SL1009 or PDCD, or if the FDA has accepted it or if there is any other BioCentury article about it. Let's do a search.

Okay, the resubmission occurs on July 7, 2026. Usually, the FDA has 30 days to decide whether to accept a resubmission (or 60 days for a standard NDA filing, but for a Class 1/2 resubmission it's 30 days, or sometimes they accept it and set a PDUFA date. Let's do a search on whether there are other updates on the watches). Wait, let's review the list of watches: 1. `Amgen Tavneos FDA hearing submission extended deadline` (July 29, 2026). Let's see if there are any updates on this. 2. `FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy` (July 29, 2026). Let's see if there are any updates or briefing docs available. 3. `FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma` (PDUFA August 2, 2026). Let's check for any updates. 4. `Sobi BLA resubmission for NASP in uncontrolled gout`. Let's check. 5. `Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN` (Q3 2026). Let's check. 6. `FDA regulatory decision on Moderna's mFlusiva mRNA flu vaccine` (PDUFA August 5, 2026). Let's check. 7. `FDA filing acceptance and PDUFA date for Belite Bio's tinlarebant` (expected early August 2026). Let's check. 8. `New Zealand H5N1 transmission to poultry or wildlife sanctuaries`. Let's check. 9. `Australia H5N1 transmission to poultry or local wildlife`. Let's check. 10. `Omeros's request for re-examination of the negative CHMP opinion for narsoplimab in TA-TMA`. Let's check. Let's run a search for Amgen Tavneos FDA hearing/re-adjudication, Capricor deramiocel, Replimune RP1, and Moderna mFlusiva.

The Amgen Tavneos FDA hearing submission is due July 29, 2026. This is still a week away (today is July 21, 2026). So it has not fired yet. Let's check on the FDA Advisory Committee meetings: 1. `Capricor's deramiocel in DMD cardiomyopathy` - scheduled for July 29, 2026. Let's see if there are any briefing documents released or updates. Usually, briefing documents are released 2 business days before the advisory committee. Today is Tuesday, July 21, 2026. July 29 is next Wednesday, so briefing documents might not be out yet (usually they come out on Friday or Monday before the meeting). Let's do a search anyway. 2. `Replimune's RP1 in advanced melanoma` - scheduled for "late July 2026" ahead of the August 2, 2026 PDUFA. Let's do a search on RP1, Replimune, Advisory Committee, and PDUFA. Let's search for Capricor deramiocel and Replimune RP1.

Okay, the Capricor Advisory Committee meeting is scheduled for July 29, 2026. The PDUFA date is August 22, 2026. Let's see if there are any updates on Replimune's RP1. Let's do a search.

Ah, the Replimune RP1 Cellular, Tissue, and Gene Therapies Advisory Committee meeting is scheduled for **July 30, 2026** (according to the Federal Register notice published July 8, 2026). Let's verify that. Yes, "will meet July 30 to review RP1 — known generically as vusolimogene oderparepvec." Let's see: the PDUFA date is August 2, 2026. So the CTGTAC committee is meeting: - July 29, 2026: Capricor's deramiocel in DMD cardiomyopathy. - July 30, 2026: Replimune's RP1 (vusolimogene oderparepvec) in advanced melanoma. Since today is July 21, 2026, both of these meetings are next week. This is an important update for the `fda-regulatory-pivot-advisory-committees-capricor-replimune` slug, or we can update it. Let's do a search on other regulatory developments or drug approvals that might have happened in the last week. Let's do a search for recent FDA drug approvals or other major trial readouts. Let's look for "FDA approval" in the last week.

Let's check on the FDA approval of Merck's Lipfendra (enlicitide), the first oral PCSK9 inhibitor, approved on July 16, 2026. This is a massive, highly consequential drug approval. Let's do a search on Merck's enlicitide (Lipfendra) and read about it. This falls directly under major drug approvals and public health moves. Let's do a web search.

Wow! This is a major update. First, on July 16, 2026, the FDA approved Merck's **Lipfendra (enlicitide)** as the first and only once-daily oral PCSK9 inhibitor. Second, the approval was granted under the **Commissioner's National Priority Voucher (CNPV)** program. Wait, let's look at the BioSpace article: "Lipfendra was approved under the FDA’s Commissioner’s National Priority Voucher (CNPV) program, an initiative launched under former commissioner Marty Makary that is designed to speed up reviews for medicines and companies aligned with certain U.S. government priorities." Wait, the article also says: "FDA disavows Makary-Prasad's papers as lawmaker blasts 'shoot-from-the-hip' policymaking" on July 17, 2026! Let's do a search on this "FDA disavows Makary-Prasad's papers" or policy changes. This is extremely relevant to our prior finding on "The Post-Makary FDA Pivot: Reversals, Resubmissions, and a Return to Advisory Committees" and "Operation Trailblazer" or FDA policy! Let's search for this immediately.

This is an incredible, multi-layered regulatory story. Let's analyze what's going on: 1. **Merck's Lipfendra (enlicitide)** was approved on July 16, 2026. It is the first and only once-daily oral PCSK9 inhibitor. It lowers LDL-C by 56% in hypercholesterolemia and 59% in HeFH. 2. Interestingly, it was approved under the **Commissioner's National Priority Voucher (CNPV)** program. This program was a signature pilot program launched under former FDA Commissioner Marty Makary (to speed up reviews from 6–12 months to 1–2 months for drugs aligning with national priorities). 3. Meanwhile, there is a major regulatory pivot: **Acting FDA Commissioner Kyle Diamantas has formally disavowed the "policymaking-via-journal-articles" practice** of former Commissioner Marty Makary and CBER Director Vinay Prasad. 4. In a letter to House Energy & Commerce ranking member Diana DeGette (and during a committee hearing on Monday, July 13, 2026), Diamantas clarified that journal articles written by Makary and Prasad (such as the *JAMA* paper requiring randomized trials for CAR-T, and the *NEJM* paper proposing the "plausible mechanism pathway" for rare genetic diseases) **do not communicate FDA policy** or set expectations for industry. Instead, official policies must go through the standard developmental and clearance processes (like the draft guidance on the plausible mechanism pathway that went through standard channels). 5. Diamantas did say that the CNPV program is still active but they are "evaluating the need to issue guidance and the agency may be further updating and refining the program based on stakeholder feedback." This perfectly updates `fda-regulatory-pivot-advisory-committees-capricor-replimune` and `hhs-clinical-trials-reform-operation-trailblazer`. Let's fetch the RAPS article or Endpoints News article to get exact quotes on this disavowal. Let's do a search to find the RAPS article URL. RAPS is `https://www.raps.org/resource/diamantas-backtracks-on-makary-s-policies-issued-in-journal-articles.html`. Let's fetch it.

This is incredibly detailed and useful! Let's see: we have two major developments that fall neatly into our existing findings. 1. **The Post-Makary FDA Pivot** (slug: `fda-regulatory-pivot-advisory-committees-capricor-replimune`): - Acting FDA Commissioner Kyle Diamantas has formally backtracked on Marty Makary's practice of "policymaking-via-journal-articles." - In a letter to Rep. Diana DeGette and confirmed during a House Energy & Commerce hearing on July 15, 2026, Diamantas stated that the *JAMA* article (on CAR-T randomized trials) and the *NEJM* article (on the "plausible mechanism pathway" for rare genetic diseases) do *not* communicate FDA policy or set industry expectations. - Diamantas also addressed concerns regarding the **Commissioner's National Priority Voucher (CNPV)** program, which was announced via an FAQ document under Makary. He stated that the agency is evaluating the need to issue formal guidance and may update or refine the program based on stakeholder feedback, while emphasizing that a voucher "does not indicate a higher likelihood of approval or any reduction in evidentiary standards." - Simultaneously, Merck's **Lipfendra (enlicitide)** was approved on July 16, 2026, as the first once-daily oral PCSK9 inhibitor. It was approved under the CNPV program (it received its voucher in December 2025). This is a monumental approval. - We can also mention the upcoming Advisory Committee meetings for Capricor's deramiocel (July 29, 2026) and Replimune's RP1 (July 30, 2026), which are slated for next week and represent the return to standard advisory committees under Diamantas. Let's check if there are other watches we can resolve or update: - `Saol's SL1009 resubmission` (slug: `hhs-clinical-trials-reform-operation-trailblazer`): - Saol Therapeutics officially resubmitted its NDA for SL1009 (sodium dichloroacetate, DCA) for the treatment of pyruvate dehydrogenase complex deficiency (PDCD) on July 7, 2026, following Type A and Type C meetings with the FDA where the agency recommended additional survival analyses instead of a new clinical trial. This is a massive update because it shows the FDA exercising "regulatory flexibility" to reverse the prior CRL (issued under the Makary era in August 2025). - This perfectly fits `hhs-clinical-trials-reform-operation-trailblazer` or `fda-regulatory-pivot-advisory-committees-capricor-replimune`. Let's see if we should reuse the slug `fda-regulatory-pivot-advisory-committees-capricor-replimune` for the FDA regulatory pivot and upcoming adcoms, and `hhs-clinical-trials-reform-operation-trailblazer` for Operation Trailblazer and Saol's resubmission, or update both. - Let's check the existing notes to see their exact titles and slugs. I'll read the notes.

There are several prior notes. Let's see: 1. `fda-regulatory-pivot-advisory-committees-capricor-replimune` is exactly the note about the post-Makary FDA pivot, reversals, resubmissions, and return to advisory committees. Let's write an update to this note. 2. `hhs-clinical-trials-reform-operation-trailblazer` is about Operation Trailblazer and the Expedited-IND program. Wait, let's also check if there is a note about Saol's SL1009. No separate note, but it is mentioned as a watch. We can write about Saol's resubmission in `hhs-clinical-trials-reform-operation-trailblazer` or in `fda-regulatory-pivot-advisory-committees-capricor-replimune`. Let's check the contents of `hhs-clinical-trials-reform-operation-trailblazer` to see what it covers. Let's search for "Operation Trailblazer" inside the notes or read it. Wait, I can search or fetch it? Ah, I don't have a specific `read_note` by slug, but I can use `write_note` to update it. Let's do a search or fetch to check if we have other recent updates. Wait, let's do a search on recent outbreaks: - `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` or `h5n1-avian-influenza-arrival-australia` or `h5n1-avian-influenza-arrival-new-zealand`. Let's see if there are any recent updates on H5N1 in Australia/New Zealand. Wait, let's search for H5N1 in New Zealand or Australia in the last week. Let's do a web search.

This is a massive development! Let's see: On July 15, 2026, New Zealand confirmed its **first-ever detection of highly pathogenic H5N1 avian influenza (clade 2.3.4.4b)** in a wild migratory brown skua found on Petone Beach in Lower Hutt (near Wellington). Just days later, on July 17, 2026, New Zealand confirmed its **second case and first-ever detection in a native resident bird**, a kāhu (swamp harrier) in the Wairarapa region. These detections have triggered immediate, sweeping biosecurity measures. Most of New Zealand's free-range poultry population has gone into a **"flockdown"**, where hundreds of thousands of free-range hens are being moved indoors to protect them from contact with wild birds. This is led by major producers like Mainland Poultry (which has over 550,000 free-range hens). Meanwhile, in Australia, on July 10, 2026, the South Australian government confirmed the first case of H5N1 in a local, resident seabird (a greater crested tern), which indicates possible local transmission (previous detections were in migratory birds like brown skuas). This is a huge development for the H5N1 virus in Oceania! It directly relates to the prior finding: `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` or `h5n1-avian-influenza-arrival-new-zealand`. Wait, let's see which slug to reuse. In our prior findings list: - `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` (preview says: "The highly pathogenic H5N1 avian influenza strain has officially breached New Zealand's borders for the first time...") Wait! Let's check the slugs in the read_notes output: - `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` (updated_at: 2026-07-21) - `h5n1-avian-influenza-arrival-new-zealand` (updated_at: 2026-07-18) - `h5n1-avian-influenza-australia-local-transmission` (updated_at: 2026-07-14) - `australia-h5n1-wildlife-transmission` (updated_at: 2026-07-13) - `australia-h5n1-avian-influenza-seabirds` (updated_at: 2026-07-09) - `australia-h5n1-avian-influenza-wild-birds-nsw-east-coast-expansion` (updated_at: 2026-07-05) - `h5n1-avian-influenza-arrival-australia` (updated_at: 2026-07-04) Wait, the most recent and comprehensive note is `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns`. Let's update `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` to capture the new "flockdown" order, the second case in the native kāhu (swamp harrier) on July 17, and the crested tern local transmission case in Australia on July 10. Wait! Let's verify if we need to write any other notes. Let's see: 1. **The Post-Makary FDA Pivot** (`fda-regulatory-pivot-advisory-committees-capricor-replimune`): - We must update this note with the July 15, 2026, Energy & Commerce hearing where Acting Commissioner Kyle Diamantas formally disavowed Makary and Prasad's journal-article-based policymaking. - We must also include the landmark approval of Merck's **Lipfendra (enlicitide)** on July 16, 2026, which is the first oral PCSK9 inhibitor and was approved under the controversial Commissioner's National Priority Voucher (CNPV) program. - We should mention the upcoming advisory committee meetings scheduled for next week: Capricor's deramiocel on July 29, 2026, and Replimune's RP1 on July 30, 2026, which represent a return to standard advisory committee processes. 2. **Operation Trailblazer and Saol's SL1009 resubmission** (`hhs-clinical-trials-reform-operation-trailblazer`): - We should update this to reflect Saol Therapeutics' NDA resubmission on July 7, 2026, for SL1009 (DCA) in PDCD. This resubmission is a direct outcome of the FDA's "demonstrated willingness to apply regulatory flexibility" following Type A and Type C meetings, allowing Saol to proceed directly to resubmission using existing data and survival analyses rather than conducting a new trial. This fits perfectly with the broader theme of clinical trials reform and regulatory flexibility. Let's review the required format for the notes: - Title is the first `# ` heading. - Slug is passed as the `slug` parameter (stable identity). - No YAML frontmatter. - Body must name and link the actual things (the stories, articles, papers). - Carry 1-2 representative verbatim quotes, copied exactly, each kept with its link. - Say what it means. - Carry a `## Sources` block. Let's double-check if there are any other active threads we can resolve: - `New Zealand H5N1 transmission to poultry or wildlife sanctuaries` (ongoing watch): Wait, the trigger is "Fires when New Zealand confirms H5N1 transmission to commercial poultry operations, wildlife sanctuaries, or local marine mammal colonies." Has it spread to commercial poultry? The articles say: "There has been no detection in poultry," said Hoggard. And "The virus has not been detected in poultry in Australia." So this watch has *not* fired yet, though they are in "flockdown" to prevent it. - `Australia H5N1 transmission to poultry or local wildlife` (ongoing watch): Trigger: "Fires when Australia confirms the transmission of H5N1 to commercial poultry flocks, native land birds, or local marine mammal colonies." Wait, did Australia confirm transmission to local wildlife or native land birds? On July 10, 2026, they confirmed it in a crested tern (a local native resident seabird). This was the first native seabird case on the mainland. Is a crested tern a "local wildlife" or "native land bird"? It's a resident native seabird. Let's see if we should record an event for `Australia H5N1 transmission to poultry or local wildlife` or wait. Let's look at the description: "Monitor whether the newly arrived H5N1 avian influenza strain jumps from migratory seabirds to local Australian wildlife, marine mammals (e.g. fur seals), or commercial poultry farms." Wait, a crested tern is a local resident seabird, so it represents a jump to local wildlife (non-migratory). Let's check: "The infected greater crested tern in South Australia marked the first confirmation that the virus had spread from migratory birds to a mainland Australia-based species." Yes! This represents a jump to local resident wildlife. We should record an event for this watch! Let's record an event with `resolves: false` (since it's an ongoing watch). - `FDA finalization and launch of Expedited-IND Pilot Program` (one_shot watch): Trigger: "Fires when the FDA announces the next phase, final guidance, or launch of the Expedited-IND Pilot Program or designates the first batch of QRIs." Has this happened yet? The RFI comment period closes on July 22, 2026 (which is tomorrow!). So it hasn't fired yet. - `FDA filing acceptance and PDUFA date for Saol's SL1009` (one_shot watch): Trigger: "Fires when the FDA accepts Saol's resubmitted NDA for SL1009 and sets a PDUFA date." Has the FDA accepted it yet? The resubmission was on July 7, 2026. The articles say: "The FDA will assign a new action (PDUFA) date upon acceptance of the file." So it hasn't been accepted yet (typically takes 30 days, which would be early August). So we wait. - `Amgen Tavneos FDA hearing submission extended deadline` (one_shot watch): Trigger: "Fires when Amgen submits its independent re-adjudication results to the FDA by the extended deadline of July 29, 2026." This deadline is July 29, 2026. Today is July 21, so it hasn't occurred yet. - `FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma` (one_shot watch): Trigger: "Fires when the FDA advisory committee meets to discuss or vote on Replimune's RP1." The meeting is scheduled for July 30, 2026. Today is July 21, so it hasn't happened yet. - `FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy` (one_shot watch): Trigger: "Fires when the FDA Cellular, Tissue, and Gene Therapies Advisory Committee votes on or discusses the approval of deramiocel." The meeting is scheduled for July 29, 2026. Today is July 21, so it hasn't happened yet. Let's record the event for the Australian H5N1 watch! Wait, let's look at the exact details of the watch: `id: 019f2f50-7f4d-7361-8f05-cdf170c2d727`, title: `Australia H5N1 transmission to poultry or local wildlife`. Let's call `record_event` on it. I will state my intent before calling the tool. Let's also write the updated notes: 1. Note 1: `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` 2. Note 2: `fda-regulatory-pivot-advisory-committees-capricor-replimune` 3. Note 3: `hhs-clinical-trials-reform-operation-trailblazer` Let's draft the body of Note 1: `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns`. Wait, let's make sure we include the quotes and links correctly. For New Zealand H5N1: - Link: `https://www.reuters.com/business/healthcare-pharmaceuticals/new-zealand-confirms-first-h5n1-bird-flu-case-native-bird-2026-07-17/` - Quote: `"While it's disappointing to find a native bird with H5 bird flu, it’s not unexpected following the confirmation earlier this week of our first case," Hoggard said.` - Link: `https://www.stuff.co.nz/nz-news/361009230/nzs-free-range-poultry-flockdown-hundreds-thousands-hens-move-indoors` - Quote: `Most of New Zealand’s free-range poultry population has gone into “flockdown”, as the industry ramps up efforts to protect birds from H5N1 bird flu.` - For Australia H5N1: - Link: `https://www.acf.org.au/news/h5n1-bird-flu-what-you-need-to-know` - Quote: `The infected greater crested tern in South Australia marked the first confirmation that the virus had spread from migratory birds to a mainland Australia-based species.` Let's draft the body of Note 2: `fda-regulatory-pivot-advisory-committees-capricor-replimune`. - Link: `https://www.raps.org/resource/diamantas-backtracks-on-makary-s-policies-issued-in-journal-articles.html` - Quote: `“Last week, the agency finally responded indicating the announcements we asked about were not in fact guidance and did not communicate FDA policies on those issues.”` - Quote: `"Evaluations have been made on a case-by-case basis, consistent with the (CNPV) pilot's need for flexibility," said Diamantas.` - Link: `https://www.biospace.com/fda/merck-dives-into-cholesterol-with-first-fda-approval-for-oral-pcsk9-inhibitor` - Quote: `Lipfendra was approved under the FDA’s Commissioner’s National Priority Voucher (CNPV) program, an initiative launched under former commissioner Marty Makary...` - Quote: `“LIPFENDRA’s label is the cleanest in the PCSK9 class, carrying zero contraindications or hypersensitivity warnings, unlike currently approved injectable competitors...”` Let's draft the body of Note 3: `hhs-clinical-trials-reform-operation-trailblazer`. - Link: `https://www.prnewswire.com/news-releases/saol-therapeutics-resubmits-the-new-drug-application-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-an-ultra-rare-disease-302816217.html` - Quote: `The resubmission follows a Type A meeting in December and a Type C meeting in March, during which the FDA provided guidance recommending additional survival analyses to support the application. This guidance enabled Saol to proceed directly to resubmission without conducting an additional trial...` - Quote: `"This resubmission reflects the totality of evidence supporting SL1009. We are committed to continuing to work collaboratively with the Agency and are encouraged by the FDA's demonstrated willingness to apply regulatory flexibility."` Let's write these notes. First, I will record the event for the Australian H5N1 watch. Then I will write the notes one by one. I will state intent before each tool call.I will record that the ongoing watch for Australian H5N1 transmission to local wildlife has fired, following the confirmation of the virus in a local resident seabird (a greater crested tern) in South Australia, which indicates possible local transmission. This does not resolve the watch as it is ongoing.

I will now write the first note, updating the H5N1 Oceania situation (`h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns`). This note details New Zealand's first detections of H5N1 in a wild brown skua and a native kāhu, the subsequent "flockdown" of hundreds of thousands of free-range hens, and Australia's first case of H5N1 in a resident native seabird.

I will now write the second note, updating the post-Makary FDA regulatory pivot (`fda-regulatory-pivot-advisory-committees-capricor-replimune`). This note covers Acting Commissioner Kyle Diamantas's historic disavowal of Makary and Prasad's journal-article-based policymaking, the landmark approval of Merck's once-daily oral PCSK9 inhibitor Lipfendra (enlicitide) under the CNPV program, and the return of standard advisory committees next week (Capricor and Replimune).

I will now write the third note, updating `hhs-clinical-trials-reform-operation-trailblazer`. This note documents Saol Therapeutics' NDA resubmission on July 7, 2026, for SL1009 (DCA) in pyruvate dehydrogenase complex deficiency (PDCD), illustrating the practical application of FDA's regulatory flexibility in rare disease clinical trials reform.

Now that I have recorded the event and written the notes updating the three critical areas of Oceania H5N1 avian influenza, the post-Makary FDA regulatory pivot and disavowal, and the clinical trials reform / Saol resubmission, I will finish the research cycle. I will pass the empty string for `no_findings_reason` because we wrote several findings this cycle. I will first state my intent.

I have completed this research cycle on topic `019e92c9-9dac-7a47-a1f2-f8f4037c94f9`. Here is a summary of the key findings and updates: ### 1. H5N1 Avian Influenza Breaches New Zealand & Spreads to Resident Seabirds in Australia * **New Zealand Detections:** On July 15, 2026, New Zealand confirmed its first-ever case of highly pathogenic H5N1 avian influenza (clade 2.3.4.4b) in a migratory brown skua near Wellington. By July 17, the virus was detected in a native resident bird—a kāhu (swamp harrier) in the Wairarapa. * **Poultry Industry "Flockdown":** To prevent contact with wild birds, the vast majority of New Zealand's free-range poultry producers have implemented a temporary "flockdown," moving hundreds of thousands of hens indoors (including over 550,000 hens managed by Mainland Poultry). * **Australian Resident Wildlife Jump:** In Australia, South Australian officials confirmed the first case of H5N1 in a resident native seabird (a greater crested tern) on July 10, 2026, marking a critical transition from migratory-only detections to local wildlife transmission. * **Updated Note:** `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` * **Watch Recorded:** Registered event for the ongoing watch `Australia H5N1 transmission to poultry or local wildlife`. ### 2. The Post-Makary FDA Pivot: Formal Disavowal of "Journal-Article" Policymaking * **Formal Disavowal:** During a House Energy & Commerce hearing on July 15, 2026, Ranking Member Diana DeGette (D-CO) revealed that Acting FDA Commissioner Kyle Diamantas has formally disavowed the practice of announcing major regulatory changes through journal articles, podcasts, or television appearances. Diamantas clarified that Marty Makary and Vinay Prasad's influential papers in *JAMA* (CAR T-cell trials) and the *NEJM* ("plausible mechanism pathway") do not constitute official FDA guidance or policy. * **Merck's Lipfendra Approval:** On July 16, 2026, the FDA approved Merck's **Lipfendra (enlicitide)**, the first-ever once-daily oral PCSK9 inhibitor to lower LDL cholesterol, bypassing the "needle barrier" of injectable competitors with a remarkably clean label (zero contraindications or hypersensitivity warnings). Lipfendra was approved under Marty Makary's controversial **Commissioner's National Priority Voucher (CNPV)** program. While honoring this voucher, Diamantas signaled that the CNPV program is undergoing evaluation and potential refinement based on stakeholder feedback. * **Advisory Committees Restored:** The FDA’s return to standard, public-facing regulatory channels will be highlighted next week with two major Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meetings: Capricor's deramiocel for DMD cardiomyopathy (July 29) and Replimune's RP1 for advanced melanoma (July 30). * **Updated Note:** `fda-regulatory-pivot-advisory-committees-capricor-replimune` ### 3. Practical Trial Reforms: Saol's SL1009 Resubmission Under Regulatory Flexibility * **SL1009 Resubmission:** On July 7, 2026, Saol Therapeutics announced the resubmission of its NDA for **SL1009 (sodium dichloroacetate / DCA)** for the treatment of pyruvate dehydrogenase complex deficiency (PDCD), an ultra-rare mitochondrial disease. * **Bypassing New Trials:** Following constructive Type A and Type C meetings, the FDA exercised "regulatory flexibility" by guiding Saol to perform survival and functional analyses on existing Phase 3 and open-label extension datasets. This allowed Saol to proceed directly to resubmission, saving years of trial development time and millions of dollars—a major win aligning with the goals of HHS's **"Operation Trailblazer"** clinical trials reform initiative. * **Updated Note:** `hhs-clinical-trials-reform-operation-trailblazer`